Wos İndeksli Yayınlar Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/11727/4807
Browse
2 results
Search Results
Item Shear Wave Velocity Measurements of the Median Nerve in Patients on Chronic Hemodialysis(2020) Yalcin, Kadihan; Demir, Bilge Cakar; 32249947; ABC-5286-2020Objectives Chronic dialysis causes changes in the structure of median nerve. This is a risk for the development of carpal tunnel syndrome in patients on dialysis. The aim of the present study was to evaluate the diagnostic capacity of shear wave velocity (SWV) and the cross-sectional area (CSA) to detect the structural changes of the median nerve in patients with end-stage chronic kidney disease on hemodialysis. Methods Twenty-five patients with chronic kidney disease undergoing hemodialysis 3 times per week and 26 healthy controls were included. None of the participants had any signs or symptoms of carpal tunnel syndrome specified according to the criteria of the American Academy of Neurology Practice Parameters. Both patients and controls underwent sonographic and elastographic examinations of the median nerves in both hands to evaluate CSA and SWV values, and they were compared regarding these parameters. Results The mean CSA of the median nerve in the chronic hemodialysis group was significantly higher than that in the control group (12.74 +/- 1.88 mm(2) versus 8.89 +/- 1.45 mm(2); P < .001). The mean longitudinal and axial SWV values in the hemodialysis group (3.86 +/- 0.54 m/s and 3.92 +/- 0.52 m/s, respectively) were significantly higher than those in the control group (2.98 +/- 0.31 m/s and 3.04 +/- 0.31 m/s, respectively; P < .001). Conclusions Patients on chronic hemodialysis had higher mean CSA and SWV values of the median nerve compared with the healthy controls. Structural changes in the median nerve that occur in patients on chronic hemodialysis can be detected by shear-wave sonoelastogrItem Experience with antiviral agents for treatment of hepatitis C virus infection in hemodialysis patients on the kidney wait list(2019) Torun, Dilek; Soydas, Baris; Tekkarismaz, Nihan; Ozelsancak, Ruya; Micozkadioglu, Hasan; Haberal, Mehmet; 30762283Introduction Hepatitis C virus (HCV) infection is associated with increased mortality and morbidity in kidney transplant patients. The ability to establish a sustained viral response before renal transplant is important for these patients. Direct-acting antiviral agents can increase the sustained viral response in most patients with HCV infection. In this case series, we aimed to determine the efficacy and safety of a combined therapy of ombitasvir, paritaprevir, ritonavir, and dasabuvir with or without ribavirin in patients with HCV genotype 1 infection without cirrhosis and on hemodialysis who were awaiting deceased-donor kidney transplant. Methods Our study included eight male and two female HCV ribonucleic acid (RNA)-positive hemodialysis patients (mean age 50.7 +/- 15 years, mean hemodialysis duration 14 +/- 5.5 years, mean HCV duration 18 +/- 3.7 years). Findings Three patients with genotype 1a received oral therapy with 12.5 mg ombitasvir, 150 mg paritaprevir, 7 5 mg ritonavir, and 250 mg dasabuvir plus 200 mg ribavirin for 12 weeks. Seven patients with genotype 1b received 12.5 mg ombitasvir, 150 mg paritaprevir, 75 mg ritonavir, and 250 mg dasabuvir without ribavirin treatment for 12 weeks. The sustained virologic response rate was 100% at 12 weeks after completion of antiviral treatment in both treatment groups. No serious adverse effects were observed in either treatment group. Five patients had constitutional symptoms such as nausea, anorexia, and fatigue. During the treatment period, hemoglobin, white cell blood count, thrombocyte, and ferritin levels were similar to pretreatment levels. Treatment did not affect weekly erythropoietin and monthly intravenous iron treatment doses. Discussion Direct-acting antiviral agents are safe and effective for generating a sustained viral response in HCV genotype 1-infected hemodialysis patients on kidney wait lists.